These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

138 related items for PubMed ID: 29147810

  • 1. Acceptability of a Tenofovir Disoproxil Fumarate Vaginal Ring for HIV Prevention Among Women in New York City.
    Watnick D, Keller MJ, Stein K, Bauman LJ.
    AIDS Behav; 2018 Feb; 22(2):421-436. PubMed ID: 29147810
    [Abstract] [Full Text] [Related]

  • 2. Acceptability of an extended duration vaginal ring for HIV prevention and interest in a multi-purpose ring.
    Stoner MCD, Browne EN, Gundacker HM, Hawley I, Chen BA, Hoesley C, Scheckter R, Piper J, Singh D, Song M, Liu A, van der Straten A.
    PLoS One; 2022 Feb; 17(2):e0263664. PubMed ID: 35192655
    [Abstract] [Full Text] [Related]

  • 3. Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial.
    Keller MJ, Wood L, Billingsley JM, Ray LL, Goymer J, Sinclair S, McGinn AP, Marzinke MA, Frank B, Srinivasan S, Liu C, Atrio JM, Espinoza L, Mugo N, Spiegel HML, Anderson PL, Fredricks DN, Hendrix CW, Marrazzo J, Bosinger SE, Herold BC.
    Lancet HIV; 2019 Aug; 6(8):e498-e508. PubMed ID: 31320290
    [Abstract] [Full Text] [Related]

  • 4. Acceptability of a Tenofovir Disoproxil Fumarate Intravaginal Ring for HIV Pre-Exposure Prophylaxis Among Sexually Active Women.
    Dobkin A, McWalters J, Barnett R, Ray LL, Espinoza L, McGinn AP, Atrio JM, Keller MJ.
    Sex Transm Dis; 2020 Dec; 47(12):819-824. PubMed ID: 33186337
    [Abstract] [Full Text] [Related]

  • 5. Safety and pharmacokinetics of single, dual, and triple antiretroviral drug formulations delivered by pod-intravaginal rings designed for HIV-1 prevention: A Phase I trial.
    Vincent KL, Moss JA, Marzinke MA, Hendrix CW, Anton PA, Pyles RB, Guthrie KM, Dawson L, Olive TJ, Butkyavichene I, Churchman SA, Cortez JM, Fanter R, Gunawardana M, Miller CS, Yang F, Rosen RK, Vargas SE, Baum MM.
    PLoS Med; 2018 Sep; 15(9):e1002655. PubMed ID: 30265679
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Qualitative Study on the Acceptability of and Adherence to a Vaginal Ring for HIV Prophylaxis Among Adolescent Girls.
    Baker Z, Javanbakht M, Moore J, Brosnan H, Squires K, Bunge K, Zimet G, Mensch B, Soto-Torres L, Kapogiannis B, Levy L, Hoesley C, Reirden D, Gaur A, Mayer K, Futterman D, Gorbach P.
    J Acquir Immune Defic Syndr; 2021 Jul 01; 87(3):944-950. PubMed ID: 33675614
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Ogbuagu O, Ruane PJ, Podzamczer D, Salazar LC, Henry K, Asmuth DM, Wohl D, Gilson R, Shao Y, Ebrahimi R, Cox S, Kintu A, Carter C, Das M, Baeten JM, Brainard DM, Whitlock G, Brunetta JM, Kronborg G, Spinner CD, DISCOVER study team.
    Lancet HIV; 2021 Jul 01; 8(7):e397-e407. PubMed ID: 34197772
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
    Baeten JM, Donnell D, Mugo NR, Ndase P, Thomas KK, Campbell JD, Wangisi J, Tappero JW, Bukusi EA, Cohen CR, Katabira E, Ronald A, Tumwesigye E, Were E, Fife KH, Kiarie J, Farquhar C, John-Stewart G, Kidoguchi L, Coombs RW, Hendrix C, Marzinke MA, Frenkel L, Haberer JE, Bangsberg D, Celum C, Partners PrEP Study Team.
    Lancet Infect Dis; 2014 Nov 01; 14(11):1055-1064. PubMed ID: 25300863
    [Abstract] [Full Text] [Related]

  • 12. An intravaginal ring for the sustained delivery of tenofovir disoproxil fumarate.
    Baum MM, Butkyavichene I, Churchman SA, Lopez G, Miller CS, Smith TJ, Moss JA.
    Int J Pharm; 2015 Nov 10; 495(1):579-587. PubMed ID: 26386138
    [Abstract] [Full Text] [Related]

  • 13. Preference of Oral Tenofovir Disoproxil Fumarate/Emtricitabine Versus Rectal Tenofovir Reduced-Glycerin 1% Gel Regimens for HIV Prevention Among Cisgender Men and Transgender Women Who Engage in Receptive Anal Intercourse with Men.
    Carballo-Diéguez A, Giguere R, Dolezal C, Leu CS, Balán IC, Brown W, Rael C, Richardson BA, Piper JM, Bekker LG, Chariyalertsak S, Chitwarakorn A, Gonzales P, Holtz TH, Liu A, Mayer KH, Zorrilla CD, Lama JR, McGowan I, Cranston RD, MTN-017 Protocol Team.
    AIDS Behav; 2017 Dec 10; 21(12):3336-3345. PubMed ID: 29119473
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
    Pleasants E, Tauya T, Reddy K, Mirembe BG, Woeber K, Palanee-Phillips T, Zimba C, Atujuna M, Montgomery ET, MTN-020/ASPIRE Study Team.
    AIDS Behav; 2020 Mar 10; 24(3):866-880. PubMed ID: 31111297
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
    van der Straten A, Panther L, Laborde N, Hoesley CJ, Cheng H, Husnik MJ, Horn S, Nel A, Soto-Torres L, Chen BA.
    AIDS Behav; 2016 Nov 10; 20(11):2644-2653. PubMed ID: 26837628
    [Abstract] [Full Text] [Related]

  • 19. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
    Krakower DS, Mayer KH.
    Drugs; 2015 Feb 10; 75(3):243-51. PubMed ID: 25673022
    [Abstract] [Full Text] [Related]

  • 20. HIV Prevention: Opportunities and Challenges.
    Marrazzo JM.
    Top Antivir Med; 2017 Feb 10; 24(4):123-126. PubMed ID: 28208119
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.